Therapy Areas: Inflammatory Diseases
Therapeutic Solutions International's QuadraMune reduces COVID-19 hyperinflammation induced by monocytes
4 January 2022 -

Therapeutic Solutions International (TSOI), a company focused on immune modulation for the treatment of several specific diseases, on Monday announced a reduction of the SARS-CoV-2 Spike Protein induced inflammation under a seven day course clinical trial of QuadraMune in 20 subjects.

Under the company's study, about ten subjects received placebo and ten received twice daily doses of QuadraMune for seven days.

The clinical study shows QuadraMune reduces COVID-19 hyperinflammation induced by monocytes. Blood monocytes were extracted and treated with SARS-CoV-2 spike protein in vitro for three time points. A significantly decreased production of the inflammatory cytokine interleukin-6 was reported at all three timepoints.

QuadraMune is the company's nutraceutical supplement that suppresses inflammatory pathways associated with COVID-19 mortality and inhibits immune suppressive enzymes including indolamine 2,3 dioxygenase, said Dr Thomas Ichim, co-inventor and board member.

In addition, the company received a notice of patent allowance for the immune modulatory and COVID-19 inhibiting properties of QuadraMune.



Related Headlines